UBS AM’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

UBS AM’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-201,900	Closed	-$2.79M	–	2693
2014 Q4	$2.79M	Buy	201,900 +10,090	+5%	+$144K	﹤0.01%	1205
2014 Q3	$2.38M	Buy	191,810 +56,248	+41%	+$776K	﹤0.01%	1248
2014 Q2	$2.47M	Sell	135,562 -2,711	-2%	-$46.4K	﹤0.01%	1251
2014 Q1	$3M	Buy	138,273 +25,516	+23%	+$739K	﹤0.01%	1179
2013 Q4	$3.99M	Buy	112,757 +91,219	+424%	+$3.06M	﹤0.01%	1060
2013 Q3	$779K	Buy	21,538 +9,425	+78%	+$429K	﹤0.01%	1597
2013 Q2	$548K	Buy	+12,113	New	+$549K	﹤0.01%	1669

Other funds holding KBIO

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS AM's KBIO Position: Q1 2015 in Review

UBS AM sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q1 2015, closing a stake of 201,900 shares — an estimated $2.79M sold.

UBS AM first reported a position in KBIO in Q2 2013 and held it in 7 quarters. The position peaked at $3.99M in Q4 2013. 24 funds tracked by Wall St. Rank hold KBIO as of Q1 2015.

UBS AM reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q1 2015 after selling out during the quarter.
UBS AM sold 201,900 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q1 2015, an estimated $2.79M.
UBS AM first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 7 quarters.
UBS AM's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $3.99M in Q4 2013.
24 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q1 2015.

Based on UBS AM's 13F filing for Q1 2015, filed 4 May 2015.